Andere Sprachen Innoviva, Inc.

Aktien

A2AC9U

US45781M1018

INVA

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 19:00:00 29.11.2024			% 5 Tage	% 1. Jan.
18.99 ^USD	-0.31%		-0.84%	+18.39%

13.11.	Innoviva, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 10:15 AM
06.11.	Innoviva, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Innoviva to Participate in the Citi 2024 Global Healthcare Conference	26.11.
Innoviva to Participate in the UBS Global Healthcare Conference	12.11.
Innoviva : Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress Form 8 K	06.11.
Innoviva: Q3 Earnings Snapshot	06.11.
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $89.5M	06.11.
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress	06.11.
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	06.11.
Innoviva Specialty Therapeutics to Present New Clinical Data from its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024	16.10.
Innoviva to Participate in Upcoming Investor Conferences	04.09.
Innoviva Specialty Therapeutics Pathogen-Targeted Antibiotic XACDURO is nominated for the 2024 Prix Galien USA Best Biotechnology Product Award	12.08.
Innoviva: Q2 Earnings Snapshot	31.07.
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	31.07.
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	31.07.
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress	31.07.
Earnings Flash (INVA) INNOVIVA Posts Q2 Revenue $99.9M	31.07.
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer	02.07.
Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer	02.07.
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	03.06.
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21.05.
Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China	20.05.
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20.05.
Innoviva: Q1 Earnings Snapshot	08.05.
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M	08.05.
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	08.05.
Innoviva, Inc. Appoints Derek Small to the Board of Directors	08.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Innoviva, Inc.

Aktien

A2AC9U

US45781M1018

INVA

Pharmazeutika

Andere Sprachen

Filter